Last updated: April 24, 2026
Adderall XR 30 mg is a branded, extended-release amphetamine mixed-salt product. Supply for this drug is constrained by (1) the FDA-licensed drug-product manufacturer of record for the commercial product, and (2) the upstream supply chain for the specific active pharmaceutical ingredient (API) grades and release-controlled formulation components used to achieve the XR profile. Publicly available sources typically identify the finished-dose NDA/ANDA product and label manufacturing sites, while API and excipient suppliers are usually not disclosed on the label.
What drug-product supplier is on the Adderall XR 30 label?
The most defensible “supplier” for Adderall XR 30 is the finished-dose manufacturer listed on the FDA label (NDA product). That manufacturer is the entity that supplies the commercial product that reaches wholesale distribution for Adderall XR.
For Adderall XR 30, the finished-dose manufacturing and label sourcing information is found on the product labeling (DailyMed) and the FDA label package.
Manufacturer identification (finished-dose drug product)
- The FDA label for Adderall XR lists a specific manufacturer for the finished dosage form (XR tablet) and often multiple listed manufacturing sites across label revisions.
- The label also lists the NDA sponsor/holder and the manufacturer of record for distribution.
What upstream suppliers (API and excipients) typically supply amphetamine XR products?
For XR amphetamine mixed salts, the upstream supply chain typically includes:
- API supplier for amphetamine mixed salts in the approved salt form(s) and particle specifications.
- Release-control excipient supplier(s) for the extended-release matrix (commonly polymeric systems used for diffusion/gel formation or layered-release architectures in XR tablets).
- Tablet film coating and printing ink suppliers used for tablet appearance, identification, and stability.
- Packaging suppliers for bottle/closure systems or blister components depending on market presentation.
However, these upstream entities generally do not appear in public label text, and supplier names are often treated as confidential business information by manufacturers and contract manufacturers.
How to map “supplier” to the highest-utility decision for R&D or procurement
Business decisions should distinguish between:
- Finished-dose manufacturer of record (direct commercial supply and regulatory accountability).
- Contract manufacturing organization (CMO) site(s) (production location that may vary by lot and label revision).
- API and excipient package suppliers (component-level substitution risk and regulatory CMC implications).
Because procurement and CMC work hinge on what can be documented from public regulatory records, the actionable supplier identification is the finished-dose manufacturer listed on the FDA label for Adderall XR.
What product data confirms that the supplier must be label-derived?
Adderall XR is regulated as a specific finished pharmaceutical dosage form. FDA labeling is the public record that ties:
- NDA holder
- dosage form and strength (30 mg)
- manufacturer of the drug product (the entity supplying the finished goods)
Regulatory anchor points
- NDC-linked label (DailyMed): the authoritative label text tied to the marketed strength.
- FDA label package: includes manufacturer and distribution information consistent with labeling at approval/revision time.
Key takeaways on Adderall XR 30 “suppliers”
- The only “supplier” that can be stated with precision from public regulatory labeling is the finished-dose manufacturer listed on the Adderall XR label for the 30 mg strength.
- API and excipient supplier identities are generally not disclosed in FDA label text for this product, and therefore cannot be stated as definitive facts from publicly available labeling alone.
- For investment or procurement due diligence, treat label manufacturer-of-record as the primary supplier counterpart and source component-level vendors through confidential supply-chain documentation, not through public labeling.
Key Takeaways
- Use the FDA label for Adderall XR 30 to identify the finished-dose manufacturer of record for the commercial product supply.
- Public sources usually do not name the API and excipient suppliers for Adderall XR.
- For CMC substitution and supply continuity planning, the procurement target should be the label-listed drug product manufacturer, then mapped internally to API/excipient vendors via documented vendor qualification.
FAQs
1) Is the supplier for Adderall XR 30 the same as the NDA holder?
Not necessarily. The NDA holder is the brand sponsor, while the label typically lists a separate manufacturer of the finished drug product.
2) Can the API supplier be confirmed from the label?
Not typically. Adderall XR labels usually do not list the API vendor name.
3) Are excipient suppliers listed for Adderall XR 30?
Generally no. Labels commonly do not disclose polymer, release-control, or ink supplier identities.
4) Do manufacturers change across label revisions?
Yes. Label revisions can add or change manufacturing sites, while the market supply continues under the same NDA with site updates.
5) What is the most defensible supplier definition for procurement?
The finished-dose manufacturer (manufacturer-of-record) shown on the FDA label for the specific strength (30 mg).
References
[1] DailyMed. “ADDERALL XR (amphetamine mixed salts) extended-release capsules.” U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/
